Results 171 to 180 of about 203,067,747 (307)

Attitudes of cancer patients toward ctDNA‐based liquid biopsy for follow‐up

open access: yesMolecular Oncology, EarlyView.
This mixed‐methods study explored cancer patients' experiences, knowledge, and preferences regarding ctDNA‐based liquid biopsy for follow‐up. Awareness of ctDNA was low and recall of previous liquid biopsy was imperfect, yet acceptance was high.
Siddharth Chhajlani   +7 more
wiley   +1 more source

Overcoming platinum resistance by the disulfiram metabolite CuET in novel preclinical models of human carcinomas

open access: yesMolecular Oncology, EarlyView.
Cisplatin‐resistant cancer cells survive DNA‐damaging platinum‐based treatment yet remain sensitive to CuET‐induced proteotoxic stress. The distinct mechanism of action allows CuET to overcome and eliminate cisplatin‐resistant tumour cells, unless highly expressed metallothioneins (MTs) interfere with CuET, thereby highlighting MT levels as candidate ...
Stefanos Arampatzis   +20 more
wiley   +1 more source

An outer membrane vesicle‐associated two‐track model for enterotoxigenic Bacteroides fragilis oncogenesis

open access: yesMolecular Oncology, EarlyView.
Enterotoxigenic Bacteroides fragilis is a gut bacterium linked to bowel cancer. We propose that its toxin acts along two routes: at the cell surface, cutting the adhesion protein E‐cadherin and triggering inflammation; and inside the cell, delivered by bacterial vesicles, switching on NOD1 and cancer stem cell programs.
Kangchan Choi   +2 more
wiley   +1 more source

Immune potentiating effects of the HDAC inhibitor Zabadinostat on human immune and tumor cells

open access: yesMolecular Oncology, EarlyView.
Zabadinostat (CXD101) is a second‐generation class I histone deacetylase inhibitor (HDACi). We show that Zabadinostat activates human T cells and natural killer cells while reducing frequencies and function of regulatory T cells. Zabadinostat also increases T cell stemness and modulates tumor cell phenotype to potentially enhance immune recognition ...
Stephanie C. Pitts   +15 more
wiley   +1 more source

Osimertinib resistance in non‐small cell lung cancer is mediated by sustained AKT activation through lipid raft‐dependent insulin signaling

open access: yesMolecular Oncology, EarlyView.
Osimertinib is effective against EGFR‐mutant NSCLC, but resistance often develops. We found that increased cholesterol in lipid rafts, specialized regions of the cell membrane, promotes recruitment of the scaffold protein FLOT1 and insulin receptors.
Yen‐Lin Lai   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy